Pharma/Biotech Update: Advate Most Prescribed Recombinant Factor
May 28, 2014; Posted by: WeBleed staff
Baxter’s factor VIII drug Advate most prescribed worldwide.
According to a press release via The Wall Street Journal, Baxter International, Inc. announced that their recombinant factor VIII (8) product, Advate, has been recognized as the most prescribed factor VIII in the world over the past year.
“Baxter has executed an array of strategic global initiatives designed to improve treatment options and expand access to quality care for hemophilia patients worldwide,” said Ludwig Hantson, Ph.D., president of Baxter BioScience. “These important achievements will allow us to build upon our global leadership and drive continued growth across our hemophilia franchise, reaching patients in both large and established markets, as well as emerging markets.”
Baxter relates the following highlights over the past year to helping them maintain success:
- Approval of a new manufacturing plant in Singapore.
- National Blood Authority in Australia designated Advate as their preferred recombinant factor VIII product.
- Approval of Advate in Turkey and Russia.
- United States Food and Drug Administration (FDA) approval of new BAXJET III system for Advate.
Currently, Advate is approved in 62 countries worldwide.
Photo Credit – Baxter International, Inc.
webleed.org – your source for bleeding news!
